Answers are grounded in this paper and cite their sources.
Does not support PON1 role in clopidogrel response; challenges prior claims and leaves open CYP2C19-focused pharmacogenetic research.
Clopidogrel is an antiplatelet agent used in the treatment of vascular diseases. It requires in vivo bio activation linked to the cytochrome P450. Several studies reported that paraoxonase-1 (PON1) was a crucial enzyme in clopidogrel activation, and that patients carrying a variant of the PON1192 gene polymorphism have a high risk of thrombosis. However, these reports were not confirmed by subsequent results. The present study was aimed at investigating whether PON1 deficiency affects the biological action of clopidogrel in mice.
No takes yet. Share an insight, caveat, or question.
Anabel García (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: